MTB and Dew:
Regarding CABG, the statement I got was, more or less,...
"we use Thrombate if we can get it, otherwise we use fresh frozen plasma"...
From which I concluded there was a desire to avoid plasma if possible. However, given the intent, at least on Leo's part,
to maintain premium pricing for the DIC indication, that leads me to think the pricing decision for the CABG indication is a sensitive one. As Dew pointed out, it may well be that if plasma is sufficiently less costly then the decision may well be to use plasma.
I'm speculating for fun but if you can make large volumes of Atryn cheaply enough, why not go for higher volume and somewhat lower price in North America? While it's not always easy to do, you can always raise the price down the road if the DIC indications prove compelling.
Market Data 
Markets 
AI
